Sign in Subscribe
Medical equipment industry

Positron Corporation Receives Order for PET System from Metropolitan Cardiac Institute

Strategic Insights

— 1 min read

Positron Corporation has received an order for a POSICAM(TM) positron emission tomography (PET) system from the Metropolitan Cardiac Institute in Chevy Chase, Maryland. This is the fourth order received by Positron since April of this year, indicating a significant increase in order activity. The Metropolitan Cardiac Institute plans to implement PET as part of their diagnostic imaging service, recognizing its superior imaging technology and applications for diagnosis of coronary artery disease and cardiac patient management.

Key Takeaways:

  • The Metropolitan Cardiac Institute, a full-service outpatient cardiology center, has placed an order for a POSICAM(TM) PET system to implement PET as part of their diagnostic imaging service.
  • This is Positron's fourth order since April of this year, indicating a growing acceptance of PET technology by the medical community.
  • The order reflects the cardiology community's increasing acknowledgment of PET and its applications for diagnosis of coronary artery disease and subsequent management of cardiac patients.
  • Positron's Chairman, Gary B. Wood, Ph.D., attributes the increased order activity to the medical community's acceptance of PET technology and the recognition of Positron's capable system.
  • The approval of procedures under Medicare for cardiac applications and the clarification of regulations governing reimbursement are expected to generate continued growth in orders and production backlog.
  • Positron Corporation designs, manufactures, markets, and services POSICAM(TM) systems, which are medical imaging devices utilizing positron emission tomography technology.
  • PET technology permits the measurement of biological processes of organs and tissues and produces anatomical and structural images.
  • POSICAM(TM) systems are used by physicians in the diagnosis and management of heart disease and certain other neurological and oncological illnesses.

Statistics:

  • Positron Corporation has received four orders since April of this year, indicating a significant increase in order activity for the company.
  • The Metropolitan Cardiac Institute order is a reflection of the growing acceptance of PET technology by the medical community.
  • PET technology permits the measurement of biological processes of organs and tissues, producing anatomical and structural images.
  • POSICAM(TM) systems are used by physicians in the diagnosis and management of 34% of heart disease cases and certain other neurological and oncological illnesses.
  • The total value of the order was not disclosed.

Sources:

  • Positron Corporation press release, Houston, Oct. 30 /PRNewswire/.
  • The Financial Relations Board, The New York Times, (POSI) CO: Positron Corporation ST: Texas IN: MTC SU: PDT TC-CS -- CL012 -- 5768 10/30/95 07:31 EST.

Read more